Literature DB >> 7966618

Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.

S W Lee1, H F Gallardo, E Gilboa, C Smith.   

Abstract

Intracellular immunization is an anti-viral gene therapy strategy based on the introduction of DNA templates into cells to stably express genetic elements which inhibit viral gene expression and replication. We have recently developed an intracellular immunization strategy for human immunodeficiency virus (HIV) infection that uses RNA decoys. RNA decoys are short RNA oligonucleotides corresponding to the HIV trans activation response element (TAR) or Rev response element (RRE) sequences, which function by inhibiting the binding of the HIV regulatory proteins Tat and Rev to the authentic HIV RNA TAR and RRE regions, respectively. In this report we describe the characterization of potent RRE decoys containing the minimal 13-nucleotide primary Rev binding domain of the RRE. Using an improved tRNA cassette to express high levels of RRE transcripts in CEM cells, we found that this new generation of minimal RRE decoys were more potent inhibitors of HIV in isolated cell lines than previously described TAR or RRE decoys. CEM cells expressing RRE decoys exhibited diminished Rev function in cotransfection assays, confirming the specificity of inhibition of HIV by RRE decoys and indicating that the 13-nucleotide minimal Rev binding domain defined by using in vitro binding studies also binds Rev in vivo. Significant differences in the degree of HIV inhibition between individual CEM cell lines transduced with RRE decoy vectors which were not due to sequence alterations in the tRNA-RRE DNA template, differences in RRE decoy expression level, or endogenous variations in the resistance of CEM clonal cell lines to HIV were observed. In order to evaluate the efficacy of RRE decoys in a more realistic fashion than by comparison of individual clonal cell lines, polyclonal populations of transduced CEM cells were infected with HIV. By using a novel flow cytometric method for quantitating intracellular p24 expression, one version of the RRE decoys tested in this study was found to be capable of durably protecting polyclonal populations of CEM cells from HIV.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7966618      PMCID: PMC237292          DOI: 10.1128/JVI.68.12.8254-8264.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Characterization of HIV-1 REV protein: binding stoichiometry and minimal RNA substrate.

Authors:  K S Cook; G J Fisk; J Hauber; N Usman; T J Daly; J R Rusche
Journal:  Nucleic Acids Res       Date:  1991-04-11       Impact factor: 16.971

2.  Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression.

Authors:  J Lisziewicz; J Rappaport; R Dhar
Journal:  New Biol       Date:  1991-01

3.  Two distinct nuclear transcription factors recognize loop and bulge residues of the HIV-1 TAR RNA hairpin.

Authors:  C T Sheline; L H Milocco; K A Jones
Journal:  Genes Dev       Date:  1991-12       Impact factor: 11.361

4.  HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA.

Authors:  D P Bartel; M L Zapp; M R Green; J W Szostak
Journal:  Cell       Date:  1991-11-01       Impact factor: 41.582

5.  Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element.

Authors:  J Kjems; M Brown; D D Chang; P A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

6.  Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication.

Authors:  B A Sullenger; T C Lee; C A Smith; G E Ungers; E Gilboa
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

7.  Identification and characterization of a nuclear factor that specifically binds to the Rev response element (RRE) of human immunodeficiency virus type 1 (HIV-1).

Authors:  Y N Vaishnav; M Vaishnav; F Wong-Staal
Journal:  New Biol       Date:  1991-02

8.  Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR.

Authors:  A Gatignol; A Buckler-White; B Berkhout; K T Jeang
Journal:  Science       Date:  1991-03-29       Impact factor: 47.728

9.  Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation.

Authors:  B A Sullenger; H F Gallardo; G E Ungers; E Gilboa
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 regulator of virion expression, rev, forms nucleoprotein filaments after binding to a purine-rich "bubble" located within the rev-responsive region of viral mRNAs.

Authors:  S Heaphy; J T Finch; M J Gait; J Karn; M Singh
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

View more
  31 in total

1.  The Rev protein is able to transport to the cytoplasm small nucleolar RNAs containing a Rev binding element.

Authors:  S B Buonomo; A Michienzi; F G De Angelis; I Bozzoni
Journal:  RNA       Date:  1999-08       Impact factor: 4.942

2.  Polyvalent Rev decoys act as artificial Rev-responsive elements.

Authors:  T L Symensma; S Baskerville; A Yan; A D Ellington
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Anti-Rex aptamers as mimics of the Rex-binding element.

Authors:  S Baskerville; M Zapp; A D Ellington
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 4.  HIV/AIDS eradication.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Bioorg Med Chem Lett       Date:  2013-05-18       Impact factor: 2.823

5.  Measuring cooperative Rev protein-protein interactions on Rev responsive RNA by fluorescence resonance energy transfer.

Authors:  Thomas Vercruysse; Sonalika Pawar; Wim De Borggraeve; Els Pardon; George N Pavlakis; Christophe Pannecouque; Jan Steyaert; Jan Balzarini; Dirk Daelemans
Journal:  RNA Biol       Date:  2011-03-01       Impact factor: 4.652

Review 6.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

7.  Fusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specifically recognizes and cleaves HIV-1 RNA in vitro.

Authors:  Y F Melekhovets; S Joshi
Journal:  Nucleic Acids Res       Date:  1996-05-15       Impact factor: 16.971

8.  Molding a peptide into an RNA site by in vivo peptide evolution.

Authors:  K Harada; S S Martin; R Tan; A D Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

Review 9.  Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.

Authors:  M Clementi; S Menzo; P Bagnarelli; A Valenza; S Paolucci; R Sampaolesi; A Manzin; P E Varaldo
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

10.  Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.

Authors:  S F Ding; J Noronha; S Joshi
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.